Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 4, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing share allocation awards for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding director share awards and does not contain financial performance data.
Material Changes
On March 31, 2006, Non-Executive Directors were provisionally allocated awards over Ordinary Shares and American Depository Shares (ADSs) for the service period of January 1, 2006, to March 31, 2006. The specific allocations are as follows:
- Sir Christopher Gent: 1,660.39 ADSs
- Mr Lawrence Culp: 519.90 ADSs
- Sir Crispin Davis: 1,328.32 ADSs
- Sir Deryck Maughan: 519.90 ADSs
- Sir Ian Prosser: 913.22 ADSs
- Dr Ronaldo Schmitz: 730.57 ADSs
- Dr Lucy Shapiro: 129.98 ADSs
- Mr Tom de Swaan: 249.06 ADSs
- Sir Robert Wilson: 415.10 ADSs
The Company and directors were informed of these allocations on April 3, 2006.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of director share transactions in accordance with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the final vesting terms and conditions of the share awards listed for Non-Executive Directors.
- Confirm the total number of ADSs and Ordinary Shares outstanding following these allocations.
- Review the full share allocation arrangements for Non-Executive Directors to understand the compensation structure for the period.